A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia

J. Kipps, Thomas; Eradat, Herbert; Grosicki, Sebastian; Catalano, John; Cosolo, Walter; Dyagil, Iryna; Yalamanchili, Sreeni; Chai, Akiko; Sahasranaman, Srikumar; A. Punnoose, Elizabeth; Hurst, Deborah; Pylypenko, Halyna

doi:10.3109/10428194.2015.1030638

Public

A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia

Published in Leukemia & lymphoma/Leukemia and lymphoma • Mar 23, 2015

Authors:

Thomas J. Kipps

Herbert Eradat

Sebastian Grosicki

Abstract

We evaluated the safety and biologic activity of the BH3 mimetic protein, navitoclax, combined with rituximab, in comparison to rituximab alone. One hundred and eighteen patients with chronic lymphocytic leukemia (CLL) were randomized to receive eight weekly doses of rituximab (arm A), eight weekly ...

Subject

Rituximab

Medicine

Chronic lymphocytic leukemia

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!